Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab

• Published in: JAAD international Vol. 16; pp. 66 - 71
• Main Authors: Gracia Cazaña, Tamara, Riera Monroig, Josep, Izu, Rosa, Yanguas, Ignacio, Lorda Espés, Marta, Sánchez Salas, María Pilar, García Gil, Miguel Fernando, Navarro Bielsa, Alba, Aldea Manrique, Beatriz, Almenara Blasco, Manuel, García-Latasa de Araníbar, Francisco Javier, Fuentelsaz, Victoria, Morales Callaghan, Ana, Ara-Martín, Mariano
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2024; Elsevier
• Subjects: individualized medicine; malignancies; Original; psoriasis; DLQI; BSA; PASI; AE; psoriasis; individualized medicine; malignancies; VAS; IL-23
• ISSN: 2666-3287; 2666-3287
• DOI: 10.1016/j.jdin.2024.02.019

The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians. To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer. We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis. Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (n = 20), including those patients with concomitant active cancers (n = 14). No adverse effects or dropouts related to guselkumab safety profile were detected. Modest sample size and the retrospective nature of the study. Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.